Cargando…

Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery

Cancer rates are increasing, and cancer is one of the main causes of death worldwide. Amygdalin, also known as vitamin B17 (and laetrile, a synthetic compound), is a cyanogenic glycoside compound that is mainly found in the kernels and pulps of fruits. This compound has been proposed for decades as...

Descripción completa

Detalles Bibliográficos
Autores principales: Spanoudaki, Maria, Stoumpou, Sofia, Papadopoulou, Sousana K., Karafyllaki, Dimitra, Solovos, Evangelos, Papadopoulos, Konstantinos, Giannakoula, Anastasia, Giaginis, Constantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531689/
https://www.ncbi.nlm.nih.gov/pubmed/37762572
http://dx.doi.org/10.3390/ijms241814270
_version_ 1785111778504474624
author Spanoudaki, Maria
Stoumpou, Sofia
Papadopoulou, Sousana K.
Karafyllaki, Dimitra
Solovos, Evangelos
Papadopoulos, Konstantinos
Giannakoula, Anastasia
Giaginis, Constantinos
author_facet Spanoudaki, Maria
Stoumpou, Sofia
Papadopoulou, Sousana K.
Karafyllaki, Dimitra
Solovos, Evangelos
Papadopoulos, Konstantinos
Giannakoula, Anastasia
Giaginis, Constantinos
author_sort Spanoudaki, Maria
collection PubMed
description Cancer rates are increasing, and cancer is one of the main causes of death worldwide. Amygdalin, also known as vitamin B17 (and laetrile, a synthetic compound), is a cyanogenic glycoside compound that is mainly found in the kernels and pulps of fruits. This compound has been proposed for decades as a promising naturally occurring substance which may provide anticancer effects. This is a comprehensive review which critically summarizes and scrutinizes the available studies exploring the anticancer effect of amygdalin, highlighting its potential anticancer molecular mechanisms as well as the need for a nontoxic formulation of this substance. In-depth research was performed using the most accurate scientific databases, e.g., PubMed, Cochrane, Embase, Medline, Scopus, and Web of Science, applying effective, characteristic, and relevant keywords. There are several pieces of evidence to support the idea that amygdalin can exert anticancer effects against lung, breast, prostate, colorectal, cervical, and gastrointestinal cancers. Amygdalin has been reported to induce apoptosis of cancer cells, inhibiting cancer cells’ proliferation and slowing down tumor metastatic spread. However, only a few studies have been performed in in vivo animal models, while clinical studies remain even more scarce. The current evidence cannot support a recommendation of the use of nutritional supplements with amygdalin due to its cyano-moiety which exerts adverse side effects. Preliminary data have shown that the use of nanoparticles may be a promising alternative to enhance the anticancer effects of amygdalin while simultaneously reducing its adverse side effects. Amygdalin seems to be a promising naturally occurring agent against cancer disease development and progression. However, there is a strong demand for in vivo animal studies as well as human clinical studies to explore the potential prevention and/or treatment efficiency of amygdalin against cancer. Moreover, amygdalin could be used as a lead compound by effectively applying recent developments in drug discovery processes.
format Online
Article
Text
id pubmed-10531689
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105316892023-09-28 Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery Spanoudaki, Maria Stoumpou, Sofia Papadopoulou, Sousana K. Karafyllaki, Dimitra Solovos, Evangelos Papadopoulos, Konstantinos Giannakoula, Anastasia Giaginis, Constantinos Int J Mol Sci Review Cancer rates are increasing, and cancer is one of the main causes of death worldwide. Amygdalin, also known as vitamin B17 (and laetrile, a synthetic compound), is a cyanogenic glycoside compound that is mainly found in the kernels and pulps of fruits. This compound has been proposed for decades as a promising naturally occurring substance which may provide anticancer effects. This is a comprehensive review which critically summarizes and scrutinizes the available studies exploring the anticancer effect of amygdalin, highlighting its potential anticancer molecular mechanisms as well as the need for a nontoxic formulation of this substance. In-depth research was performed using the most accurate scientific databases, e.g., PubMed, Cochrane, Embase, Medline, Scopus, and Web of Science, applying effective, characteristic, and relevant keywords. There are several pieces of evidence to support the idea that amygdalin can exert anticancer effects against lung, breast, prostate, colorectal, cervical, and gastrointestinal cancers. Amygdalin has been reported to induce apoptosis of cancer cells, inhibiting cancer cells’ proliferation and slowing down tumor metastatic spread. However, only a few studies have been performed in in vivo animal models, while clinical studies remain even more scarce. The current evidence cannot support a recommendation of the use of nutritional supplements with amygdalin due to its cyano-moiety which exerts adverse side effects. Preliminary data have shown that the use of nanoparticles may be a promising alternative to enhance the anticancer effects of amygdalin while simultaneously reducing its adverse side effects. Amygdalin seems to be a promising naturally occurring agent against cancer disease development and progression. However, there is a strong demand for in vivo animal studies as well as human clinical studies to explore the potential prevention and/or treatment efficiency of amygdalin against cancer. Moreover, amygdalin could be used as a lead compound by effectively applying recent developments in drug discovery processes. MDPI 2023-09-19 /pmc/articles/PMC10531689/ /pubmed/37762572 http://dx.doi.org/10.3390/ijms241814270 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Spanoudaki, Maria
Stoumpou, Sofia
Papadopoulou, Sousana K.
Karafyllaki, Dimitra
Solovos, Evangelos
Papadopoulos, Konstantinos
Giannakoula, Anastasia
Giaginis, Constantinos
Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery
title Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery
title_full Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery
title_fullStr Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery
title_full_unstemmed Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery
title_short Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery
title_sort amygdalin as a promising anticancer agent: molecular mechanisms and future perspectives for the development of new nanoformulations for its delivery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531689/
https://www.ncbi.nlm.nih.gov/pubmed/37762572
http://dx.doi.org/10.3390/ijms241814270
work_keys_str_mv AT spanoudakimaria amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery
AT stoumpousofia amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery
AT papadopoulousousanak amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery
AT karafyllakidimitra amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery
AT solovosevangelos amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery
AT papadopouloskonstantinos amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery
AT giannakoulaanastasia amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery
AT giaginisconstantinos amygdalinasapromisinganticanceragentmolecularmechanismsandfutureperspectivesforthedevelopmentofnewnanoformulationsforitsdelivery